KR101571915B1 - Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법 - Google Patents

Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법 Download PDF

Info

Publication number
KR101571915B1
KR101571915B1 KR1020107020293A KR20107020293A KR101571915B1 KR 101571915 B1 KR101571915 B1 KR 101571915B1 KR 1020107020293 A KR1020107020293 A KR 1020107020293A KR 20107020293 A KR20107020293 A KR 20107020293A KR 101571915 B1 KR101571915 B1 KR 101571915B1
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
alkoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107020293A
Other languages
English (en)
Korean (ko)
Other versions
KR20100121656A (ko
Inventor
마티아스 뮐러
베른 뮐러
토마스 마이어
Original Assignee
4에스체 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4에스체 악티엔게젤샤프트 filed Critical 4에스체 악티엔게젤샤프트
Publication of KR20100121656A publication Critical patent/KR20100121656A/ko
Application granted granted Critical
Publication of KR101571915B1 publication Critical patent/KR101571915B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020107020293A 2008-03-12 2009-03-11 Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법 Active KR101571915B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004567.7 2008-03-12
EP08004567A EP2100878A1 (en) 2008-03-12 2008-03-12 Novel method for the production of sulphonylpyrroles as HDAC inhibitors

Publications (2)

Publication Number Publication Date
KR20100121656A KR20100121656A (ko) 2010-11-18
KR101571915B1 true KR101571915B1 (ko) 2015-11-25

Family

ID=39639400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107020293A Active KR101571915B1 (ko) 2008-03-12 2009-03-11 Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법

Country Status (22)

Country Link
US (1) US8785659B2 (https=)
EP (2) EP2100878A1 (https=)
JP (1) JP5530939B2 (https=)
KR (1) KR101571915B1 (https=)
CN (1) CN101970404B (https=)
AT (1) ATE519739T1 (https=)
AU (1) AU2009224623C1 (https=)
BR (1) BRPI0909752B8 (https=)
CA (1) CA2719074C (https=)
CY (1) CY1111994T1 (https=)
DK (1) DK2265580T3 (https=)
EA (1) EA017929B1 (https=)
ES (1) ES2370592T3 (https=)
IL (1) IL207995A (https=)
MX (1) MX2010010015A (https=)
NZ (1) NZ587824A (https=)
PL (1) PL2265580T3 (https=)
PT (1) PT2265580E (https=)
SI (1) SI2265580T1 (https=)
UA (1) UA102091C2 (https=)
WO (1) WO2009112529A1 (https=)
ZA (1) ZA201006422B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
WO2017178577A1 (en) 2016-04-14 2017-10-19 4Sc Ag Medical application of resminostat in asian patients
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
HRP20130810T1 (en) 2004-03-11 2013-09-30 4Sc Ag Sulphonylpyrroles as hdac inhibitors
PT1861365E (pt) * 2005-03-15 2009-09-22 4Sc Ag N-sulfonilpirroles e a sua utilização como inibidores de histona-desacetilase
CN101287706A (zh) 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles

Also Published As

Publication number Publication date
CN101970404A (zh) 2011-02-09
IL207995A (en) 2013-04-30
US8785659B2 (en) 2014-07-22
PL2265580T3 (pl) 2012-01-31
AU2009224623C1 (en) 2014-01-23
EP2265580B1 (en) 2011-08-10
KR20100121656A (ko) 2010-11-18
US20110105568A1 (en) 2011-05-05
CN101970404B (zh) 2013-05-08
IL207995A0 (en) 2010-12-30
ZA201006422B (en) 2011-10-26
EA201001270A1 (ru) 2011-04-29
AU2009224623B2 (en) 2013-07-18
MX2010010015A (es) 2011-04-05
SI2265580T1 (sl) 2011-12-30
WO2009112529A1 (en) 2009-09-17
PT2265580E (pt) 2011-11-21
HK1150319A1 (en) 2011-11-25
NZ587824A (en) 2012-05-25
BRPI0909752B1 (pt) 2020-11-24
CA2719074C (en) 2017-01-17
BRPI0909752B8 (pt) 2021-05-25
CA2719074A1 (en) 2009-09-17
ATE519739T1 (de) 2011-08-15
EP2265580A1 (en) 2010-12-29
UA102091C2 (ru) 2013-06-10
EA017929B1 (ru) 2013-04-30
BRPI0909752A2 (pt) 2015-10-06
CY1111994T1 (el) 2015-11-04
JP5530939B2 (ja) 2014-06-25
AU2009224623A1 (en) 2009-09-17
DK2265580T3 (da) 2011-10-31
EP2100878A1 (en) 2009-09-16
JP2011513467A (ja) 2011-04-28
ES2370592T3 (es) 2011-12-20

Similar Documents

Publication Publication Date Title
ES2712803T3 (es) Inhibidores de histona desacetilasa
CN108530310B (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
KR20210052331A (ko) Ezh2 저해제　및　e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물
AU2020200846A1 (en) Piperidine derivatives as hdac1/2 inhibitors
EA012451B1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
CA2947134A1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
CA2907528A1 (en) Novel compounds
KR101571915B1 (ko) Ｈｄａｃ 저해제로서의 술포닐피롤의 신규 제조 방법
CN108689937B (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
PT2419422E (pt) Derivados de imidazolidina-2,4-diona e sua utilização como um medicamento
WO2023061368A1 (zh) 一类羟肟酸衍生物及其应用
CN118684666A (zh) Kif18a抑制剂及其用途
WO1999040063A1 (en) Novel azapeptide type hydroxamic acid derivatives
KR101900574B1 (ko) 신규한 n-히드록시벤즈아미드 및 이의 용도
WO2021082181A1 (zh) Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
HK1150319B (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
WO2025194094A1 (en) Small molecule modulators of sirt5 and uses thereof
KR20180071890A (ko) 신규한 히드록삼산 및 이의 용도
KR20120109667A (ko) 열쇼크 단백질의 활성을 저해하는 신규 화합물
Mohameda et al. Novel chalcone derivatives: Design, synthesis and histone deacetylase inhibition activity
KR20120056447A (ko) 퀴녹살린 유도체 또는 이의 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
CN114158266A (zh) 化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途
JP2020186182A (ja) 標的蛋白質分解誘導化合物
BR112020000564A2 (pt) novos derivados de heteroarilamida como inibidores seletivos das histonas desacetilases 1 e/ou 2 (hdac1-2)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100910

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150528

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20151027

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151119

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20201109

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20211111

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20221110

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20231107

Start annual number: 9

End annual number: 9